Ify Osunkwo: We invite you to join our interactive roundtable discussion
Ify Osunkwo, Chief Patient Officer at Novo Nordisk, shared on LinkedIn:
“A rare opportunity for an important discussion-We look forward to seeing you soon in Barcelona!
If you are attending the Orphan Drug Congress on 31 October 2023, why not join me Dr. Ify Osunkwo, alongside my colleagues Lora Ruth Wogu, and David-Zacharie Issom for an interactive roundtable discussion? Together, we’ll dive deep into one of the most pressing themes affecting the Rare Disease community: How can we ignite integrated, equitable, and affordable access to care?
During the discussion, we will explore the challenges people living with sickle cell face when trying to receive proper care and discuss how they can be addressed at multiple levels by each stakeholder across the healthcare system – from R&D, data collection and patient engagement to ensuring better collaborations between patient associations, industry, and health authorities, guided by the principles of patient advocacy. Leveraging these insights, we will discuss how to take these learnings forward to accelerate access to care so that more people living with rare diseases can get the treatment they deserve.
Get insights and perspectives on:
• What challenges exist for people living with sickle cell disease?
• How can these challenges be solved efficiently across the healthcare continuum?
• Why is partnership key to ensuring integrated, equitable, affordable access to care?
And how to take these learnings forward!
We invite you to join our interactive roundtable discussion: Ensuring integrated, equitable and affordable access to care: sickle cell disease as a case study.
Join us at WODC on:
Oct. 31st, 11:30 – 12:30 CEST and let’s discuss!
Source: Ify Osunkwo/LinkedIn.
-
17:28 29/11JeeSuk Chang: A multi-center trial - great efforts from the KROG team
-
17:00 29/11Maite Bourlon: Access to novel drugs for metastatic renal cell carcinoma is an unmet need in the Mexican population
-
23:17 28/11Manni Mohyuddin: Current trials must have observation/surveillance as control arm
-
23:04 28/11Juan P. Alderuccio: Our approach to secondary CNS involvement by aggressive lymphomas
-
17:17 27/11Vivek Subbiah: Treatment patterns and overall survival (OS) in patients with advanced NSCLC in three countries between 2011 and 2020
-
17:43 28/11Michele Carbone: The world is full of good, honest, nice people
-
17:24 28/11Jessica Clerc: Celebrating 90 Years of Excellence and Dedication in Cancer Care!
-
17:44 25/11Carlos Pedraz: Congratulations, Dr. Rafael Rosell for the very well deserved 2023 ISLB Lifetime Achievement Award
-
17:10 25/11100 Influential Celebrities in Oncology: The 2023 Edition – Part 4
-
13:34 24/11"Bald for a Cause" initiative - UWC Dilijan College
-
17:34 28/11The International Association of Cancer Registries annual conference - IARC
-
18:05 26/11Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
17:58 26/11Lisa A. Lacasse: My sincere gratitude to the ACS CAN team, our incredible volunteers, and supporters for another outstanding year
-
16:47 16/11How social determinants can influence a patient’s ability to stay in treatment - ASCO
-
13:22 16/11SIOP Europe Student Summer School for Paediatric Oncology
-
17:25 29/11NIH Director’s Early Independence Award supports junior scientists to launch independent careers - National Cancer Institute
-
17:07 29/11Santhosh Kumar Devadas: I’m starting a new position as a Professor of Medical Oncology and Chief of Bone Marrow Transplant at Ramaiah Memorial Hospital and Ramaiah Medical College
-
16:48 27/11CRCHD seeks motivated scientists to serve as Program Directors - NCI Disparities
-
16:25 27/11Luisa Basset completed a fruitful nine-year tenure on the CCI board of trustees - Childhood Cancer International
-
18:14 26/11Tristan Knight: Attention hematology / oncology and pediatric hematology / oncology fellows